16548-07-5

Basic information

• Product Name: Ethylsulfamoyl chloride
• Synonyms: Ethylsulfamoyl chloride;Ethylsulphamoylchloride;Ethylamidosulfonyl chloride;Ethylaminosulfonyl chloride;N-Ethylchlorosulfonamide
• CAS NO: 16548-07-5
• Molecular Formula: C₂H₆ClNO₂S
• Molecular Weight: 143.59254
• Mol File: 16548-07-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 96-98 °C(Press: 0.2 Torr)
• Appearance: /
• Density: 1.397±0.06 g/cm3(Predicted)
• PKA: 7.84±0.40(Predicted)
• CAS DataBase Reference: Ethylsulfamoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ethylsulfamoyl chloride(16548-07-5)
• EPA Substance Registry System: Ethylsulfamoyl chloride(16548-07-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 16548-07-5(Hazardous Substances Data)

Usage

Uses

N-Ethylchlorosulfonamide is used in the preparation of flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease.

Synthesis Reference(s)

The Journal of Organic Chemistry, 41, p. 4028, 1976 DOI: 10.1021/jo00887a022

Upstream product

• 4626-94-2 ethylaminosulfonic acid 
• 75-04-7 ethylamine 
• 557-66-4 ethanamine hydrochloride 
• 7791-25-5 sulfuryl dichloride 

Downstream Products

• 26120-06-9 N-Aethyl-N'-phenyl-sulfonyldiamid 
• 26120-10-5 N-Benzyl-N'-ethyl-sulfonyldiamid 
• 68967-73-7 (5-tert-Butyl-2-ethylsulfamoyloxy-3-iodo-benzyl)-carbamic acid tert-butyl ester 
• 80-39-7 N-ethyl-4-methyl-benzenesulfonamide 
• 96855-43-5 2-Oxo-cyclohexanesulfonic acid ethylamide 
• 57836-25-6 Ethyl-sulfamic acid [(2,6-dimethyl-phenyl)-methoxymethyl-carbamoyl]-methyl ester 
• 136166-36-4 ethylsulfamic acid 2-[[(ethylamino)sulfonyl]oxy]-3-(2-methoxyphenoxy)propyl ester 
• 136166-37-5 ethylsulfamic acid 2-[[(ethylamino)sulfonyl]oxy]-3-phenoxypropyl ester 
• 936213-89-7 (C₆H₅)3CSC₄H₆NCO₂CH₂CHCH₂CNOCH₃CH₂NHSO₂NHCH₂CH₃ 
• 263843-19-2 toluene-4-thiosulfonic acid S-[2-(1,1-dimethylethyl)-4-[[(ethylamino)sulfonyl]amino]-5-methylphenyl] ester 
• 207737-21-1 toluene-4-thiosulfonic acid S-(2-tert-butyl-4-ethylsulfamoyloxy-5-methyl-phenyl) ester 
• 70484-59-2 2-morpholin-4-yl-1,2-diphenyl-ethenesulfonic acid ethylamide 

Relevant articles and documents

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR

The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.